Terminated PHASE2 INTERVENTIONAL 1-arm NCT00831480

Everolimus (RAD001) For Advanced Renal Cell Carcinoma (RCC) Before Kidney Removal

Neoadjuvant Everolimus (RAD001)for Advanced RCC Before Cytoreductive Nephrectomy, With Correlative Tumor Studies (Protocol #: 06-08-20-01)

Sponsor: Linda C. Higgins

Conditions Kidney Cancer

Interventions everolimus

Updated 8 times since 2017 Last updated: Feb 19, 2016 Started: Apr 30, 2011 Primary completion: Nov 30, 2013 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Difficulty in accrual and by the order of the cancer center.

Other Kidney Cancer trials with similar outcome

Browse all Kidney Cancer trials

This PHASE2 trial investigates Kidney Cancer and is currently terminated or withdrawn. Linda C. Higgins leads this study, which shows 8 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE2
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE2
Jan 2021 — Dec 2022 [monthly]

Terminated PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE2
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE2

First recorded

Apr 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Linda C. Higgins
University of Texas Southwestern Medical Center

Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Dallas, United States
• Houston, United States